CD95 ligand expression enhances growth of murine renal cell carcinoma in vivo

Cancer Immunology Immunotherapy

Volumn 48, Issue 1, 1999, Pages 56-61

  Nishimatsu, Hiroaki ^a   Takeuchi, Takumi ^a   Ueki, Tetsuo ^a   Kajiwara, Takahiro ^a   Moriyama, Nobuo ^a   Ishida, Toshimitsu ^a   Li, Baoxing ^a   Kakizoe, Tadao ^b   Kitamura, Tadaichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

Author keywords

Apoptosis Tumor growth; CD95L; FasL; Renca

Indexed keywords

FAS ANTIGEN; LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; HISTOPATHOLOGY; IMMUNE RESPONSE; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; CARCINOMA, RENAL CELL; CELL DIVISION; CLONING, MOLECULAR; DNA, COMPLEMENTARY; FAS LIGAND PROTEIN; KIDNEY NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, NUDE; TRANSFECTION;

EID: 0032951095     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050548     Document Type: Article

References (15)

1. 1. Arai H, Gordon D, Nabel EG, Nabel GJ (1997) Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 94:13-862
2. 2. Bellgrau D, Gold D, Selawry H, Moore J, Franzuzoff A, Duke RC (1995) A role for CD95 ligand in preventing graft rejection. Nature 377:630
3. 3. Ferguson TA, Griffith TS (1997) A vision of cell death: insights into immune privilege. Immunol Rev 156:167
4. 4. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG, Baekkeskov S (1997) Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 3:738
5. 5. Nagata S, Suda T (1995) Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39
6. 6. Niwa H, Yamamura K, Miyazaki J (1991) Efficient selection for high-expression transfectant with a novel eukaryotic vector. Gene 108:193
7. 7. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F (1996) The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075
8. 8. Seino K, Kayagaki N, Tsukada N, Fukao N, Yagita H, Okumura K (1997) Transplantation of CD95 ligand-expressing grafts: influence of transplantation site and difficulty in protecting allo- and xenografts. Transplantation 64:1050
9. 9. Seino K, Kayagaki N, Okumura K, Yagita H (1997) Antitumor effect of locally produced CD95 ligand. Nat Med 3:165
10. 10. Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariant SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells-a mechanism of immune evasion? Nat Med 2:1361
11. 11. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S (1994) Generalized lymphoproliferative diseases in mice, caused by a point mutation in the Fas ligand. Cell 76:969
12. 12. Takeuchi T, Sasaki T, Ueki T, Kaziwara T, Moriyama N, Kawabe K, Kakizoe T (1996) Modulation of growth and apoptosis response in PC-3 and LNCAP prostate cancer cell lines by Fas. Int J Cancer 67:709
13. 13. Takeuchi T, Ueki T, Sasaki Y, Kajiwara T, Li B, Moriyama N, Kawabe K (1997) Th2-like response and anti-tumor effect of anti-IL-4 mAb in mice bearing renal cell carcinoma. Cancer Immunol Immunother 43:375
14. 14. Watanabe-Fukunage R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA, Nagata S (1992) The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 148:1274
15. 15. Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS (1997) Fas-Fas ligand-based interactions between tumor cells and tumor specific cytotoxic T lymphocytes: a lethal two-way street. Blood 90:1952